Related Experiment Video
Updated: May 26, 2026
Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
Published on: November 13, 2012
Volociximab in cancer
Salah Almokadem1, Chandra P Belani
1Penn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA.
Introduction:
Volociximab is a first-in-class chimeric monoclonal antibody that targets α5β1 integrin. Preclinical studies have shown the ability of volociximab to inhibit tumor neoangiogenesis by blocking the interaction between α5β1 and fibronectin. Volociximab's safety profile, pharmacokinetics and pharmacodynamics have been established. Ongoing clinical trials are evaluating its efficacy in the treatment of different types of solid tumors as a single agent or in combination with chemotherapy. In this review we focus on the biological effect of volociximab and results of completed clinical trials.
Areas Covered:
This review summarizes the structures and functions of integrin α5β1 and its ligand fibronectin, provides an overview of the early development of volociximab, a targeted monoclonal antibody that specifically binds and inhibits activation of integrin α5β1, and discusses the relevant data from pre-clinical and clinical studies.
Expert Opinion:
Volociximab has been well tolerated as monotherapy or in combination with chemotherapy. It has shown promising activity in different types of cancer. Randomized trials are required to validate those early results.
Insights
Volociximab, an antibody targeting α5β1 integrin, shows promise in treating solid tumors by inhibiting angiogenesis. Clinical trials indicate it is well-tolerated and effective, warranting further randomized studies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Volociximab is a novel chimeric monoclonal antibody targeting the α5β1 integrin receptor.
- Preclinical data demonstrate its potential to inhibit tumor angiogenesis by blocking α5β1 integrin-fibronectin interactions.
Purpose of the Study:
- To review the biological effects of volociximab.
- To summarize findings from completed clinical trials evaluating volociximab in solid tumors.
Main Methods:
- Review of scientific literature on integrin α5β1, fibronectin, and volociximab.
- Analysis of preclinical and clinical study data for volociximab's efficacy and safety.
Main Results:
- Volociximab has a well-established safety profile and pharmacokinetic/pharmacodynamic characteristics.
- Early clinical trials suggest promising anti-cancer activity for volociximab as a single agent or in combination therapy.
Conclusions:
- Volociximab is well-tolerated in monotherapy and combination regimens.
- Further randomized clinical trials are necessary to confirm the efficacy of volociximab in various cancer types.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...